#United States #San Francisco #Bexion Pharmaceuticals #BXQ-350 #ASCO Symposium

Bexion Pharmaceuticals Sets Stage at ASCO 2026

Bexion Pharmaceuticals, Inc., a pioneering company in clinical-stage biopharmaceuticals, is gearing up to showcase significant advances at the upcoming American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026. Scheduled for January 8-10, 2026, in San Francisco, California, this event will provide a prominent platform for Bexion to present three key posters detailing the efficacy and safety of their lead drug candidate, BXQ-350.

About BXQ-350

BXQ-350 represents a groundbreaking approach in the treatment of solid tumors and chemotherapy-induced peripheral neuropathy (CIPN). This first-in-class biologic therapy, featuring sphingolipid metabolism modulation, has been a focal point in multiple Phase 1 clinical trials. Its safety profile has been robustly established across various solid tumor types, demonstrating its potential not only as a cancer treatment but also in addressing the side effects arising from traditional chemotherapeutic agents.

Poster Presentations at ASCO 2026

Bexion Pharmaceuticals will present three posters at the ASCO symposium:

1. Abstract Title: Efficacy and Safety Evaluation of BXQ-350 in First Line mCRC Patients
This study investigates the use of BXQ-350 in conjunction with mFOLFOX7 and bevacizumab for newly diagnosed metastatic colorectal carcinoma patients.
- Abstract Number: 242
- Session Date: January 10, 2026
- Presenter: Dr. Reema Patel

2. Abstract Title: Phase 1b/2 Study on BXQ-350
This poster outlines the study of BXQ-350’s efficacy and safety in combination with standard treatments for mCRC patients.
- Abstract Number: TPS273
- Session Date: January 10, 2026
- Presenter: Dr. Tariq Arshad

3. Abstract Title: Effect of BXQ-350 on Oxaliplatin-Induced CIPN
This presentation will focus on BXQ-350's efficacy in mitigating CIPN effects in mCRC treatment settings.
- Abstract Number: 105
- Session Date: January 10, 2026
- Presenter: Michael Gazda, Ph.D.

The Need for Innovation

The landscape of cancer treatment is ever-evolving, and Bexion’s commitment to innovating biologics places it at the forefront of therapeutic advancements. With increasing incidences of solid tumors and the widespread use of chemotherapeutic agents, solutions that alleviate side effects such as CIPN are critical. BXQ-350 not only seeks to treat the cancer itself but also enhance the quality of life for patients undergoing intensive treatment regimens.

Conclusion

Bexion Pharmaceuticals is not only presenting promising data but also setting a standard for what the future of cancer therapy could look like. As they prepare for their presentations at ASCO 2026, the biopharmaceutical community watches with bated breath for insights that could reshape treatment protocols and improve patient outcomes. With a strong scientific foundation and enthusiastic participation in major oncology events, Bexion is paving the way for more effective strategies to combat cancer and its associated challenges.

For more information or inquiries, please reach out to Joyce LaViscount at Bexion Pharmaceuticals via email or call at 859-446-7386.